Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $53 Price Target
Benzinga · 11/07/2023 15:42
Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.